Evotec SE stock (DE0005664809): after delisting shock, what’s next for the biotech group?

Evotec SE has completed its delisting from the Frankfurt Stock Exchange and is grappling with strategic shifts and governance changes. What the latest developments could mean for the drug discovery specialist and for investors following European biotech from the US.

Evotec SE has entered a new phase after its delisting from the Frankfurt Stock Exchange’s Prime Standard segment became effective on March 29, 2024, following a January 26, 2024 decision by the exchange, according to a company announcement published on January 26, 2024 and March 28, 2024 on its website and via Deutsche Börse filings (Evotec corporate communication as of 01/26/2024; Börse Frankfurt notice as of 03/28/2024). The biotechnology company, focused on drug discovery and development partnerships, positions the step as part of a broader strategic and financing realignment while investors reassess liquidity and governance structures.

As of: 05/23/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology / drug discovery
• Headquarters/country: Hamburg, Germany
• Core markets: Global pharmaceutical and biotech partnerships
• Key revenue drivers: Research collaborations, milestones, service fees
• Home exchange/listing venue: Previously Frankfurt (Prime Standard)
• Trading currency: Euro (EUR)

Evotec SE: core business model

Evotec SE describes itself as a drug discovery and development platform company that works primarily for pharmaceutical and biotechnology partners. The group provides integrated research services from early target identification through preclinical development, aiming to de-risk projects and improve productivity for large pharma clients, according to its corporate profile updated in 2024 on the company’s website (Evotec company information as of 2024-2025). Rather than focusing mainly on fully self-funded proprietary drugs, Evotec typically co-develops assets and earns revenue through a mix of upfront payments, research funding, milestone payments and royalties.

This partnership-driven model means Evotec’s success is closely tied to its ability to attract and retain large, long-term collaborations with global pharmaceutical groups and increasingly with smaller biotech and academic institutions. The company reports platforms and capabilities across multiple therapeutic areas, including neurology, metabolic diseases and oncology, which it organizes in both fee-for-service projects and risk-sharing alliances, as outlined in its reporting for the 2023 financial year published in April 2024 (Evotec FY 2023 results release as of 04/24/2024).

The company also invests in what it calls co-owned pipeline projects, where Evotec contributes R&D efforts or capital in exchange for a share in future milestones and royalties. This hybrid structure introduces potential upside if partnered drugs progress successfully through clinical development but also adds complexity to financial reporting and risk management. Investors tend to follow the evolution of this pipeline closely because the timing of milestones can materially affect quarterly results while remaining difficult to predict.

Main revenue and product drivers for Evotec SE

Evotec divides its business into segments centered around contract research and development platforms. For the 2023 financial year, the company highlighted revenue growth driven mainly by its base business in fee-for-service contracts and funded research collaborations, according to the annual results publication dated April 24, 2024 (Evotec FY 2023 results release as of 04/24/2024). In these contracts, Evotec typically generates relatively predictable revenue over multi-year project periods, providing visibility compared with milestone-driven income.

Beyond the base services, partnered pipeline assets represent another key value driver, though one with a longer time horizon. When a compound that has been co-developed with Evotec progresses into later-stage clinical trials or obtains regulatory approval, the company may receive pre-agreed milestone payments and potentially recurring royalties on sales. Because the probability of success for any single drug project is inherently uncertain, the company aims to mitigate risk by maintaining a broad portfolio of partnerships across various therapeutic areas.

Evotec has also been expanding its capabilities in biologics and cell therapy research, which are seen as growth areas within the pharmaceutical industry. The company’s network of research sites in Europe and North America supports this expansion, with investments into laboratory capacity and technology platforms mentioned in several corporate updates in 2023 and 2024. These investments are intended to make Evotec a partner of choice for complex discovery programs but also lead to higher short-term operating costs, which can pressure margins if revenue growth does not keep pace.

Conclusion

Evotec SE is navigating a period of transition following its delisting from the Frankfurt Stock Exchange, as highlighted in communications from January and March 2024. The company continues to pursue a partnership-based business model centered on drug discovery services and a growing co-owned pipeline, which offers potential upside but also exposes earnings to milestone volatility. For observers in the US and Europe alike, the main questions now revolve around how Evotec will balance investment in new platforms with profitability and how its financing and governance setup will evolve without a Prime Standard listing. The answers to these questions will depend on the company’s ability to sustain collaboration momentum and manage execution risk in a competitive and capital-intensive sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.